SAGE 217

Drug Profile

SAGE 217

Alternative Names: SAGE-217

Latest Information Update: 09 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator SAGE Therapeutics
  • Class Antidepressants; Antiepileptic drugs; Antiparkinsonians; Sleep disorder therapies; Small molecules
  • Mechanism of Action GABA A receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Seizures

Highest Development Phases

  • Phase II Essential tremor; Major depressive disorder; Parkinson's disease; Postnatal depression
  • Phase I Insomnia; Seizures
  • Preclinical Dyskinesias

Most Recent Events

  • 02 Nov 2017 Adverse events and efficacy data from the part A of phase II trial in Essential tremor released by Sage Therapeutics (NCT02978781)
  • 02 Nov 2017 Adverse events and efficacy data from the part B of phase II trial in Parkinson's disease released by Sage Therapeutics (NCT03000569)
  • 18 Sep 2017 Sage Therapeutics completes a phase II trial in Parkinson's disease in USA (PO) (NCT03000569)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top